| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/9783527634057.CH20 |
| P50 | author | Ronit Satchi-Fainaro | Q19758708 |
| P2093 | author name string | Dina Polyak | |
| Anat Eldar-Boock | |||
| P2860 | cites work | Targeting Tumor Vasculature: Reality or a Dream? | Q57617360 |
| Integrin-regulated FAK-Src signaling in normal and cancer cells | Q24300271 | ||
| Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N | Q24317442 | ||
| Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity | Q24561642 | ||
| Targeting selectins and selectin ligands in inflammation and cancer | Q24658204 | ||
| Tumor angiogenesis: therapeutic implications | Q27860595 | ||
| Integrins: bidirectional, allosteric signaling machines | Q27860700 | ||
| Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins | Q28202564 | ||
| Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin | Q28239719 | ||
| Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis | Q28260742 | ||
| Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target | Q28266775 | ||
| Mechanisms of disease: the role of heat-shock protein 90 in genitourinary malignancy | Q28272747 | ||
| Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth | Q28323559 | ||
| The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells | Q28474747 | ||
| Integrins in cancer: biological implications and therapeutic opportunities | Q29614536 | ||
| Angiogenesis: an organizing principle for drug discovery? | Q29614538 | ||
| Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule | Q29616413 | ||
| Angiogenesis as a therapeutic target | Q29619525 | ||
| N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists | Q30580638 | ||
| Solution stability of linear vs. cyclic RGD peptides | Q30744942 | ||
| An address system in the vasculature of normal tissues and tumors | Q30874647 | ||
| Drug targeting to specific vascular sites | Q30883393 | ||
| Specialization of tumour vasculature | Q30896811 | ||
| Combinatorial discovery of tumor targeting peptides using phage display | Q31005417 | ||
| Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model | Q32145219 | ||
| Cyclic RGD peptide-conjugated polyplex micelles as a targetable gene delivery system directed to cells possessing alphavbeta3 and alphavbeta5 integrins | Q33289019 | ||
| Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics | Q33432776 | ||
| Hyaluronan: a multifunctional, megaDalton, stealth molecule | Q34026287 | ||
| Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma | Q34066263 | ||
| Families of zinc metalloproteases. | Q34325403 | ||
| RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo | Q34379366 | ||
| VEGF receptor signal transduction | Q34461939 | ||
| The hyaluronan receptor, CD44. | Q34598130 | ||
| RNAi therapeutics: principles, prospects and challenges | Q34621268 | ||
| A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship | Q34690734 | ||
| Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. | Q34693504 | ||
| Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models | Q34770116 | ||
| Regulation of the metastatic process by E-selectin and stress-activated protein kinase-2/p38. | Q35027257 | ||
| Selectins-an emerging target for drug delivery. | Q35669922 | ||
| CD13/APN is activated by angiogenic signals and is essential for capillary tube formation | Q35751643 | ||
| Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives | Q35781708 | ||
| CD13/APN regulates endothelial invasion and filopodia formation | Q35850653 | ||
| Integrin signalling during tumour progression | Q35906078 | ||
| Polymer therapeutics: concepts and applications | Q36380938 | ||
| Mitochondria and cancer: Warburg addressed | Q36547748 | ||
| Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism | Q36611736 | ||
| Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer | Q36667452 | ||
| Peptides which bind to E-selectin and block neutrophil adhesion | Q36679423 | ||
| Endothelial cell adhesion molecules and cancer progression | Q36737909 | ||
| The structure and main functions of aminopeptidase N. | Q36754546 | ||
| Dendrimers in oncology: an expanding horizon | Q37355900 | ||
| Pertactin, an Arg-Gly-Asp-containing Bordetella pertussis surface protein that promotes adherence of mammalian cells | Q37367187 | ||
| Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel | Q37378199 | ||
| Clustering and internalization of integrin alphavbeta3 with a tetrameric RGD-synthetic peptide. | Q37383038 | ||
| Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency | Q37480688 | ||
| Breast cancer: understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicine. | Q37481556 | ||
| Degradable polyethylenimines as DNA and small interfering RNA carriers | Q37532552 | ||
| Targetable HPMA copolymer-aminohexylgeldanamycin conjugates for prostate cancer therapy | Q37635384 | ||
| Small molecule integrin antagonists in cancer therapy | Q37636249 | ||
| HPMA copolymer-cyclic RGD conjugates for tumor targeting | Q37642122 | ||
| Hsp90: a drug target? | Q37738758 | ||
| The selectins and their ligands | Q38304052 | ||
| Activity screening and structure-activity relationship of the hit compounds targeting APN/CD13. | Q39679483 | ||
| In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers | Q39715659 | ||
| Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate. | Q39717127 | ||
| The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin | Q39789312 | ||
| Tumor-endothelium cross talk blocks recruitment of neutrophils to endothelial cells: a novel mechanism of endothelial cell anergy | Q39793034 | ||
| E-selectin binding peptide-polymer-drug conjugates and their selective cytotoxicity against vascular endothelial cells | Q39806556 | ||
| Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier | Q39826157 | ||
| In vitro and in vivo evaluation of a paclitaxel conjugate with the divalent peptide E-[c(RGDfK)2] that targets integrin alpha v beta 3. | Q39919998 | ||
| Selectins ligand decorated drug carriers for activated endothelial cell targeting | Q39938034 | ||
| Hyaluronic acid-polyethyleneimine conjugate for target specific intracellular delivery of siRNA. | Q40005275 | ||
| MDA-MB-435 cells are derived from M14 melanoma cells--a loss for breast cancer, but a boon for melanoma research | Q40227151 | ||
| Alpha-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells | Q40288837 | ||
| Nanoparticles for the optical imaging of tumor E-selectin | Q40359393 | ||
| Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator | Q40532812 | ||
| Syntheses and some applications of chemically defined multivalent glycoconjugates | Q41206802 | ||
| Selectin-carbohydrate interactions during inflammation and metastasis | Q41594933 | ||
| Cracking the carbohydrate code for selectin recognition | Q41651480 | ||
| Anti-cancer activity of targeted pro-apoptotic peptides | Q41688099 | ||
| De novo antimicrobial peptides with low mammalian cell toxicity | Q42810129 | ||
| New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties | Q43597572 | ||
| Influence of the structure of drug moieties on the in vitro efficacy of HPMA copolymer-geldanamycin derivative conjugates | Q43908844 | ||
| Tumor regression by targeted gene delivery to the neovasculature | Q44044889 | ||
| Fractionation and characterization of a conjugate between a polymeric drug-carrier and the antitumor drug camptothecin | Q44222038 | ||
| Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting | Q44284738 | ||
| Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. | Q44775111 | ||
| Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation | Q45082801 | ||
| Tumor-specific gene delivery mediated by a novel peptide-polyethylenimine-DNA polyplex targeting aminopeptidase N/CD13. | Q45259478 | ||
| PEG conjugated N-octyl-O-sulfate chitosan micelles for delivery of paclitaxel: in vitro characterization and in vivo evaluation. | Q46017742 | ||
| Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. | Q46079015 | ||
| Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate | Q46084536 | ||
| Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer | Q46507139 | ||
| The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine | Q47582503 | ||
| A mitochondrial targeted fusion peptide exhibits remarkable cytotoxicity. | Q52573063 | ||
| Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. | Q53144257 | ||
| Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. | Q53686513 | ||
| Development of PEGylated doxorubicin-E-[c(RGDfK)2] conjugate for integrin-targeted cancer therapy | Q57617348 | ||
| Rational Design of Multifunctional Polymer Therapeutics for Cancer Theranostics | Q57617355 | ||
| P304 | page(s) | 591-625 | |
| P577 | publication date | 2011-12-16 | |
| P1476 | title | Ligand-Assisted Vascular Targeting of Polymer Therapeutics |
| Q47959735 | Integrin-targeted nano-sized polymeric systems for paclitaxel conjugation: a comparative study. | cites work | P2860 |
Search more.